|
Related Companies
|
[]
|
||||||||
|
Related Funds
|
[]
|
||||||||
|
|
|||||||||
|
English
|
|||||||||
|
oda_MaterialEventDisclosureGeneralAbstract|
|
|
||||||||
|
oda_UpdateAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_CorrectionAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_DateOfThePreviousNotificationAboutTheSameSubject|
|
|
-
|
|||||||
|
oda_DelayedAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_AnnouncementContentSection|
|
|
||||||||
|
oda_ExplanationSection|
|
|
||||||||
|
oda_ExplanationTextBlock|
|
-Unofficial Translation- An exclusive distribution agreement ("Agreement") signed between Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. ("GEN") and a Company named Guerbet ("Guerbet"), where is located in 15 rue des Vanesses, 93420 Villepinte, France on 12.12.2023. In accordance with the signed Agreement, GEN will have the sales and marketing rights in Türkiye for the drug named "LIPIODOL® ULTRA-FLUID 480 MG/10 ML INJECTION SOLUTION 10 ML 1 AMPUL" produced by Guerbet. Within the framework of the provisions of this contract, the registration of the drug which currently registered in the name of GUERBET İlaç Tıbbi Malzeme ve Cihazlar San. ve Tic. A.Ş. in our Country will be transferred to our Company and after the completion of the relevant legal processes, GEN will start the sales and marketing activities of this drug.
|
||||||||